(NBTX) Nanobiotix - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.597m USD | Total Return: 1303.3% in 12m
Industry Rotation: -4.2
Avg Turnover: 2.83M
Warnings
Negative Equity with losses - insolvent profile
Interest Coverage Ratio -4.4 is critical
Beneish M-Score -0.15 > -1.5 - likely earnings manipulation
Altman Z'' -10.51 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind, Confidence
Nanobiotix S.A. (NBTX) is a French clinical-stage biotechnology firm specializing in nanomedicine for oncology. The company’s core technology utilizes NBTXR3, a radioenhancer composed of hafnium oxide nanoparticles designed to increase the dose of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. This physical mechanism of action distinguishes it from traditional systemic drug therapies that rely on chemical interactions.
The company targets a broad range of solid tumors, including head and neck, liver, and lung cancers. To facilitate global distribution, Nanobiotix employs a regional licensing model, evidenced by its partnership with LianBio to develop and commercialize its lead candidate across key Asian markets. In the biotechnology sector, such partnerships are critical for clinical-stage firms to offset high R&D costs and navigate complex regulatory environments in foreign jurisdictions.
Investors looking for deeper technical analysis and valuation metrics should consult ValueRay for further data. Researching the specific clinical trial phases for each targeted indication will provide a clearer picture of the companys path to potential commercialization.
- NBTXR3 clinical trial data readouts drive investor sentiment and valuation
- Janssen partnership milestones and royalty payments provide critical non-dilutive funding
- Regulatory approval timelines for head and neck cancer impact market entry
- Global expansion through LianBio partnership determines penetration in Asian markets
- Cash runway and future equity financing activities influence long-term capital structure
| Net Income: -92.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.80 > 0.02 and ΔFCF/TA -68.23 > 1.0 |
| NWC/Revenue: 23.35% < 20% (prev 42.66%; Δ -19.31% < -1%) |
| CFO/TA -0.78 > 3% & CFO -53.0m > Net Income -92.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.8m) vs 12m ago 1.48% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 29.08% > 50% (prev 64.74%; Δ -35.66% > 0%) |
| Interest Coverage Ratio: -4.43 > 6 (EBITDA TTM -79.2m / Interest Expense TTM 18.5m) |
| A: 0.08 (Total Current Assets 62.8m - Total Current Liabilities 57.5m) / Total Assets 67.8m |
| B: -0.35 (Retained Earnings -24.0m / Total Assets 67.8m) |
| C: -1.06 (EBIT TTM -81.8m / Avg Total Assets 77.2m) |
| D: -2.62 (Book Value of Equity -398.7m / Total Liabilities 152.2m) |
| Altman-Z'' Score: -10.51 = D |
| DSRI: 6.15 (Receivables 7.68m/3.12m, Revenue 22.5m/56.1m) |
| GMI: 0.49 (GM 100.0% / 48.86%) |
| AQI: 1.20 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.40 (Revenue 22.5m / 56.1m) |
| TATA: -0.58 (NI -92.1m - CFO -53.0m) / TA 67.8m) |
| Beneish M-Score: -0.15 (Cap -4..+1) = D |
Over the past week, the price has changed by +13.21%, over one month by +55.12%, over three months by +94.27% and over the past year by +1303.27%.
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 34.1 | -33.8% |
P/E Forward = 77.5194
P/S = 79.6777
P/B = 65.0172
Revenue TTM = 22.5m EUR
EBIT TTM = -81.8m EUR
EBITDA TTM = -79.2m EUR
Long Term Debt = 89.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 4.31m EUR (from shortTermDebt, last quarter)
Debt = 95.3m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 42.6m EUR (from netDebt column, last quarter)
Enterprise Value = 2.26b EUR (2.22b + Debt 95.3m - CCE 52.8m)
Interest Coverage Ratio = -4.43 (Ebit TTM -81.8m / Interest Expense TTM 18.5m)
EV/FCF = -41.54x (Enterprise Value 2.26b / FCF TTM -54.4m)
FCF Yield = -2.41% (FCF TTM -54.4m / Enterprise Value 2.26b)
FCF Margin = -242.1% (FCF TTM -54.4m / Revenue TTM 22.5m)
Net Margin = -410.2% (Net Income TTM -92.1m / Revenue TTM 22.5m)
Gross Margin = unknown ((Revenue TTM 22.5m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 33.33 (Enterprise Value 2.26b / Total Assets 67.8m)
Interest Expense / Debt = 7.08% (Interest Expense 6.75m / Debt 95.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -64.6m (EBIT -81.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.09 (Total Current Assets 62.8m / Total Current Liabilities 57.5m)
Debt / Equity = -1.13 (negative equity) (Debt 95.3m / totalStockholderEquity, last quarter -84.5m)
Debt / EBITDA = -0.54 (negative EBITDA) (Net Debt 42.6m / EBITDA -79.2m)
Debt / FCF = -0.78 (negative FCF - burning cash) (Net Debt 42.6m / FCF TTM -54.4m)
Total Stockholder Equity = -71.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -119.3% (out of range, set to none)
RoE = 129.3% (negative equity) (Net Income TTM -92.1m / Total Stockholder Equity -71.2m)
RoCE = -456.7% (out of range, set to none) (EBIT -81.8m / Capital Employed (Equity -71.2m + L.T.Debt 89.1m))
RoIC = -835.3% (out of range, set to none) (NOPAT -64.6m / Invested Capital 7.74m)
WACC = 7.71% (E(2.22b)/V(2.31b) * Re(7.80%) + D(95.3m)/V(2.31b) * Rd(7.08%) * (1-Tc(0.21)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 89.89 | Cagr: 15.09%
[DCF] Fair Price = unknown (Cash Flow -54.4m)
EPS Correlation: -10.26 | EPS CAGR: 20.81% | SUE: 1.21 | # QB: 1
Revenue Correlation: 4.18 | Revenue CAGR: 38.63% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.07 | Chg30d=+163.99% | Revisions=-20% | GrowthEPS=+114.5% | GrowthRev=+52.6%
EPS next Year (2027-12-31): EPS=0.13 | Chg30d=+101.45% | Revisions=+20% | GrowthEPS=+72.5% | GrowthRev=-2.4%
[Analyst] Revisions Ratio: -20%